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GPI-anchored CCL28 as a strong mucosal
immunostimulator with inﬂuenza VLPs
T. Mohan ∗, R.W. Compans, B. Wang
Emory School of Medicine, Atlanta, GA, USA
Background: Inﬂuenza presents amajor health problem, affect-
ing hundreds of millions of people with high morbidity and
mortality. Because of the importance of immunological regulations
at mucosa, protection provided at the pathogen’s entry site, and
promising results with different infectious diseases at mucosa, in
both clinical and experimental settings, it would be advantageous
to study the mucosal adjuvant with inﬂuenza antigens.
Methods & Materials: The M1, HA/M1, HA/M1/GPI-CCL28 VLPs
were prepared by co-infecting sf9 insect cells with rBVs express-
ing M1, HA and GPI-CCL28. The surface expression and in-vitro
chemotactic activity towards CCR3+/CCR10+cells of GPI-CCL28
were checkedusing ﬂowcytometry. All preparedVLPswere charac-
terized and immunized in mice intranasally. The IgG/IgA responses
were investigated in sera, tracheal, lung, and intestinal washes. We
analyzed CD4+IFN-+cells for proliferation and CD8+CD107a+cells
for cytolytic activitiesusingFACSat spleen, lung,mediastinal lymph
nodes, and peyer’s patches. The Th1/Th2 cytokine and IgG/IgA
secreting cells were estimated using ELISPOT while total concen-
tration were checked by sandwich ELISA. Protective studies were
evaluated in animals across distantly related subtypes.
Results: The HA/M1/GPI-CCL28 VLPs showed in-vitro
chemotactic activity for CD3+/CCR3+/CCR10+cells and
CD19+/CCR3+/CCR10+cells. The end point titer for IgG in sera
and IgA in mucosal washes ranged between 51200-102400 and
6400-12800 respectively, in HA/M1/GPI-CCL28 VLPs, signiﬁcantly
(p<0.0001) higher (4-6 fold) thanHA/M1VLPs alone orHA/M1VLPs
with sCCL28 (soluble) with signiﬁcantly higher IgG/IgA secreting
cells. The IgG2a was observed higher than IgG1, indicating Th1
type of immune response. The HAI titer was signiﬁcantly (p<0.001)
higher (3-5 fold) in antibodies with HA/M1/GPI-CCL28 VLPs
than other formulations. The HA/M1/GPI-CCL28 VLPs induced
cell proliferation but not encouraged cytolytic activities. Dur-
ing cytokine estimations, a high IFN- and IL-2 with low IL-4
and TNF- were observed. Protective efﬁcacy was determined
by challenging with A/Aichi/2/1968/H3N2 (homologous) and
A/Philippines/2/1982/H3N2 (drifted) viruses and showed 100%
and 80% survival in respective viruses, with no signiﬁcant body
weight lose, in the group of HA VLPs containing GPI-CCL28.
Conclusion: The GPI-CCL28 in inﬂuenza VLPs act as a strong
immunostimulator at both systemic and mucosal sites when com-
pared with inﬂuenza VLPs without CCL28, or inﬂuenza VLPs mixed
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Serological and molecular investigation of
dengue, chikungunya and rift valey fever in
febrile and non-febrile patients from northern
Mozambique during Dengue outbreak, 2014
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Background: Arboviruses represent themost rapidly spreading
mosquito-borne viruses worldwide. In Mozambique, arboviroses
have been heavily neglected and for this reason they are never
considered in the differential diagnosis of acute febrile illness. A
recent dengue outbreak was reported in Pemba, situated in north-
ernMozambique in2014, andduring theoutbreakmore thanhalf of
dengue suspected cases had their dengue results negative, suggest-
ing other causes of fever of unknown origin. The aim of the study
was to investigate the circulation of dengue (DENV), chikungunya
(CHIKV), west nile virus (WNV) and rift valley fever (RVF) in febrile
and non febrile patients in Pemba, during the outbreak of dengue
in 2014.
Methods & Materials: A total of 398 individuals were identi-
ﬁed, of which, 300 were non febrile and 98 were dengue suspected
cases (febrile) attending the outpatient appointment visit at Pemba
Provincial Hospital, between March and April 2014 were enrolled
in this study. Blood samples were collected from each participant
and initially tested for dengue using IgM anti-dengue commercial
ELISA and by real time PCR. All dengue negative samples were then
tested for chikungunya, RVFV, WNV using the PCR and indirect
immunoﬂuorescence assay (IFA) for IgG detection.
Results: Of the 398 participants 37.7% (37/98) were DENV posi-
tive using PCR and allwere negative for CHIKV, RVF andWNVwhen
testedbyPCR. Among febrile patients, IgG antibodies against CHIKV
were detected in 27.5% (27/98) of febrile participants by IFA, 10.2%
(10/98) were dual positive for IgG anti-DENV and IgG anti-CHIKV
and 3.06% (3/98) were positive for IgG anti-RVF. The percentage
of positive results for IgG antibodies against DENV, CHIKV, RVFV
among non febrile participantswere 26% (78/300), 45.3% (136/300)
and 1% (3/300), respectively. No sample was positive for IgG anti-
WNV antibody among non febrile patients.
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Conclusion: Our data provide evidence that DENV, CHIKV and
RVF co-circulate in northernMozambique, suggesting that not only
DENV but CHIKV and RVFV, should be considered in the differential
diagnosis of acute febrile syndrome in northern Mozambique.
http://dx.doi.org/10.1016/j.ijid.2016.02.430
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Leishmania disease gap analysis study -
Pakistan
S.M. Mursalin
National Health Information Resource Center,
Islamabad, ICT, Pakistan
Background: Pakistan is rated among one of the high Leish-
mania prevalent countries. The rising incidence of Leishmania in
Pakistan aremarkedbypoverty, poorhealthcare, inadequate vector
control, refugees, inadequate healthcare system and drug short-
ages. Disease is being reported from all over the country specially
the remote underserved mountainous areas of Sindh, Khyber and
Baluchistan provinces.
To address this Pakistan OneHealth Alliance (POHA) in part-
nership with Ministry of Health Services (MOHS), and partners
undertook, ﬁrst ever, Gap Analysis Study in during April – October
2015. Plan was not only to identify gaps between diagnosis and
management, but also, to help suggest a strategic plan to improve
diagnosis, treatment, control and disease prevention.
Methods & Materials: A multidimensional approach was
adopted to undertake this study. Primarily this was a cross sec-
tional study based on questionnaire survey. Questionnaire were
developed for multiple levels of healthcare system including com-
munity and patients. Data was captured from all over the country
including some of the refugees camps.
Results: Cutaneous Leishmania (CL) is reportable under in
National Health Information Systems. Clear inter provincial differ-
ences exist for disease reporting. 15 districts were found very high
disease incidence. Unfortunately, for this disease there is neither
an exclusive control program or integrated with some other dis-
ease. Only 38% of the facilities surveyed had adequate manpower
and diagnostic facilities for the disease. There existed issues with
availability of efﬁcient detection and response system, staff train-
ing and availability of drugs. In about 50% of facilities there existed
severe drug shortage. Despite the high cost antimony injectionwas
the main line of treatment for CL. This was followed by glucantine
and cryotherapy. These drugs are neither manufactured.
Conclusion: Disease control demand greater political commit-
ment by all stakeholders. Aggressive health education campaigns,
inter sectoral collaboration, proper vector control, drug supply and
preventive measures are desired to address this menace.
http://dx.doi.org/10.1016/j.ijid.2016.02.431
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Synthetic DNA encoded antibody prophylaxis
confers rapid protective immunity in vivo
against Chikungunya virus infection
K. Muthumani1,∗, P. Block1, S. Flingai1, N.
Muruganantham2, I.K. Chaaithanya2, G.
Sarangan3, P. Srikanth4, P. Vijayachari2, N.Y.
Sardesai5, J.J. Kim5, K. Ugen6, D. Weiner1
1 Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, USA
2 ICMR, Port Blair, Andaman & Nicobar Islands, India
3 Sri Ramachandra Medical College & Research
Institute, Chennai, India
4 Sri Ramachandra University, Cheannai, India
5 Inovio Pharmaceutics, Plymouth Meeting, USA
6 University of South Florida Morsani College of
Medicine, Tampa, USA
Background: Chikungunya (CHIKV) disease is a serious emerg-
ing mosquito-transmitted viral infection responsible for epidemic
outbreaks. Currently, no licensed vaccines or therapies are avail-
able against this virus, resulting in signiﬁcant global spread with
concurrent population morbidity.
Methods & Materials: This study describes a novel immune-
based intervention that utilizes in vivo deliver of synthetic DNA
plasmids encoding a monoclonal antibody (mAb) targeting the
CHIKV envelope protein.
Results: Importantly, a single intramuscular injection with a
DNA plasmid expressing an anti-CHIKV mAb produced antibodies
in mice more rapidly than vaccination with CHIKV-Env-encoding
DNA plasmids. DNA-mediated delivery of anti-CHIKV antibodies
neutralizeddiverse clinical isolates in vitro andprotectedmice from
lethal CHIKV challenge.
Conclusion: This study illustrates the ability of antibody-
encoding plasmids to induce rapid protection against CHIKV
highlighting the potential of this novel immunoprophylaxis and
therapeutic applications platform for other emerging infectious
pathogens.
http://dx.doi.org/10.1016/j.ijid.2016.02.432
